Annovis Bio, Inc. (NYSE: ANVS)
$12.59
+0.4300 ( +3.54% ) 505.1K
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
Market Data
Open
$12.59
Previous close
$12.16
Volume
505.1K
Market cap
$141.21M
Day range
$12.08 - $12.97
52 week range
$4.53 - $22.49
SEC Fillings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 8-k | 8K-related | 15 | Apr 03, 2024 |
| 10-k | Annual reports | 85 | Mar 29, 2024 |
| 8-k | 8K-related | 13 | Mar 22, 2024 |
| 8-k | 8K-related | 14 | Mar 21, 2024 |
| 8-k | 8K-related | 14 | Mar 20, 2024 |
| 8-k | 8K-related | 13 | Mar 20, 2024 |
| 8-k | 8K-related | 15 | Mar 15, 2024 |
| 4/a | Other | 1 | Nov 22, 2023 |
| 4/a | Other | 1 | Nov 22, 2023 |
| 4/a | Other | 1 | Nov 22, 2023 |